About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4456472
Allelic
Composition
Gstm1tm1Gcw/Gstm1tm1Gcw
Genetic
Background
involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gstm1tm1Gcw mutation (0 available); any Gstm1 mutation (8 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• valproic acid (VPA) treatment reduces crawl-under social play behavior unlike in similarly treated wild-type mice
• VPA fails to decrease allogrooming or paired horizontal movement unlike in similarly treated wild-type mice
• VPA-treated mice exhibit increased paired horizontal movement than similarly treated wild-type mice
• mice exhibit decreased paired horizontal movement compared with wild-type mice
• mice exhibit increased crawl-under social play behavior compared with wild-type mice
• VPA-treated mice exhibit less crawl-under social play behavior than similarly treated wild-type mice
• following treatment with sodium valproate at P14, female mice exhibit decreased allogrooming compared with wild-type female
• however, allogrooming in female and male mice is the same as in wild-type male mice

nervous system
• female mice exhibit increased VPA-induced granule cell apoptosis in the cerebellum and hippocampus compared with wild-type female
• however, levels of apoptosis in female and male mice are the same as in wild-type male mice
• mice exhibit increased cerebellum dopamine levels compared with wild-type mice
• male mice exhibit increased frontal cortex dopamine levels regardless of VPA treatment compared with similarly treated wild-type mice
• however, VPA treatment increases dopamine to levels observed in similarly treated wild-type mice

homeostasis/metabolism
• mice exhibit increased cerebellum dopamine levels compared with wild-type mice
• male mice exhibit increased frontal cortex dopamine levels regardless of VPA treatment compared with similarly treated wild-type mice
• however, VPA treatment increases dopamine to levels observed in similarly treated wild-type mice
• mice exhibit increased cerebellum serotonin levels compared with wild-type mice
• however, VPA treatment lowers cerebellum serotonin levels
• VPA treatment decreases cerebellum serotonin levels unlike in similarly treated wild-type mice
• however, VPA treatment lowers cerebellum serotonin levels and increases dopamine to levels observed in similarly treated wild-type mice

cellular
• female mice exhibit increased VPA-induced granule cell apoptosis in the cerebellum and hippocampus compared with wild-type female
• however, levels of apoptosis in female and male mice are the same as in wild-type male mice

Mouse Models of Human Disease
OMIM ID Ref(s)
Autism 209850 J:159701


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/17/2016
MGI 6.05
The Jackson Laboratory